Table 2.
Multivariate analysis of Participant Characteristics and Likelihood of Seroconversion.
| Adjusted Hazard Ratio (95% CI) | Significance | |
|---|---|---|
| Sex | ||
| Female | Ref | Ref |
| Male | 0.92 (0.87–0.98) | 0.0082 |
| Age | ||
| 18–40 years | Ref | Ref |
| 41–65 years | 0.68 (0.64–0.73) | <0.0001 |
| 66–95 years | 0.55 (0.50–0.60) | <0.0001 |
| Race/ethnicity | ||
| Other race/ethnicity1 | Ref | Ref |
| White (not Hispanic/Latino) | 0.85 (0.72–0.99) | 0.0365 |
| History of seropositivity2 | ||
| No | Ref | Ref |
| Yes | 1.70 (1.35–2.15) | <0.0001 |
| Vaccine received | ||
| Moderna mRNA-1273 | Ref | Ref |
| Pfizer BNT162b2 | 0.83 (0.77–0.88) | <0.0001 |
| Symptomatic after first dose | ||
| No | Ref | Ref |
| Yes | 1.00 (0.94–1.07) | 0.9594 |
| Symptomatic after second dose | ||
| No | Ref | Ref |
| Yes | 1.11 (1.05–1.17) | 0.0004 |
1
Other race/ethnicity included Asian, American Indian or Alaska Native, Black or African American, Hispanic/Latino, Native Hawaiian/Other Pacific Islander, those who identified as Other, and those who did not or did not wish to specify their race.
2
History of previous positive serologic assay. The last serologic assay prior to vaccination was required to be negative for inclusion in this study.